Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Atezolizumab boosts outcomes in squamous NSCLC

Jotte et al. ASCO 2018 Abstract LBA9000.

Key clinical point: Adding atezolizumab to first-line chemotherapy for squamous NSCLC improves outcomes.

Major finding: Compared with chemotherapy alone, chemotherapy plus atezolizumab prolonged median progression-free survival from 5.6 to 6.3 months (hazard ratio, 0.71; P = .0001).

Study details: A phase 3 randomized, controlled trial among 1,021 all-comer (PD-L1–unselected), chemotherapy-naïve patients with stage IV squamous NSCLC (IMpower131 trial).

Disclosures: Dr. Jotte disclosed that he is on the speakers’ bureau for Bristol-Myers Squibb, and that he receives travel, accommodations, and/or expenses, as well as honoraria from Bristol-Myers Squibb. The study received funding from F. Hoffmann-La Roche Ltd.

Source: Jotte et al. ASCO 2018 Abstract LBA9000.

Read the article.

Citation:

Jotte et al. ASCO 2018 Abstract LBA9000.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Lung Cancer

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

Prophylactic cranial irradiation boosts OS in advanced NSCLC , Arrieta O et al. WCLC 2018, Abstract MA08.02.

Nivolumab safe and effective for cancer patients with HIV, Gobert et al. ESMO 2018, Abstract 1213P_PR.

CT scans cut lung cancer deaths, A presentation at the World Conference on Lung Cancer